Curis (CRIS) shares rallied 19.5% in the last trading session to close at $16.01. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 37.3% gain over the past four weeks. The stock rallied due to the optimism over the development of the company’s lead candidate, emavusertib, which is being evaluated in mid-stage studies for treating various cancer indications like primary central nervous system lymphoma, acute my ...